P2, N=40, Recruiting, Sun Yat-sen University

P2, N=96, Recruiting, Avalyn Pharma Inc. | N=64 --> 96

P2, N=100, Recruiting, National Cancer Institute (NCI) | Trial completion date: Apr 2026 --> Apr 2029 | Trial primary completion date: Apr 2026 --> Apr 2029

P=N/A, N=10646, Completed, Boehringer Ingelheim | Active, not recruiting --> Completed

In vivo, combined treatment with anlotinib and RAD51-IN-1 significantly reduced tumor burden without notable toxicity. These findings suggest that RAD51-mediated HRR may contribute to anlotinib resistance and support RAD51 inhibition as a promising approach to overcome therapeutic resistance in ovarian cancer.

Subsequently, the CML burden declined as the AML clone regrew. This case highlights the importance of accurately assessing clonal changes using genetic analysis when implementing molecular targeted therapy for hematologic malignancies.

The results of functional experiments showed that knockdown of LGALS3 could inhibit cell proliferation and invasion and promote apoptosis, while affecting drug sensitivity to Dasatinib. In summary, this study constructed a robust prognostic model based on T-HIERDEGs, systematically revealed the immune and molecular characteristics of different risk groups, explained the heterogeneity of T cell subpopulations in the hypoxic microenvironment and their potential role in immune escape, and provided a new theoretical basis and candidate targets for the prognosis assessment, immunotherapy, and combined strategies of HCC.

Our findings demonstrate that laparoscopic caudate lobectomy after neoadjuvant therapy is a feasible approach for managing resectable HCC with high risk of recurrence located in the caudate lobe.

First-generation inhibitors, such as midostaurin, provided the foundation for targeted therapy, while recently developed agents such as gilteritinib and quizartinib have shown more selectivity and demonstrated superior clinical efficiency and improved tolerability. This review discusses the significance of FLT-3 mutations, the evolution of targeted therapies, current treatment guidelines, and ongoing challenges such as resistance and high relapse rates. We also discuss the emerging combinations of therapies and novel agents currently in clinical trials that aim to overcome resistance and improve long-term outcomes for patients with FLT-3-mutated AML.

P=N/A, N=6, Terminated, University Hospital, Rouen | N=64 --> 6 | Not yet recruiting --> Terminated; Changes in the indication for Sunitinib in metastatic renal cell carcinoma, which have led to a significant decrease in its use in the urology department. Collected data will not be sufficient to perform a statistical analysis.

P=N/A, N=100, Completed, Istituto Oncologico Veneto IRCCS | Active, not recruiting --> Completed

These findings establish that lenvatinib inhibits HCC by regulating lipid metabolism through the PDGF/GFR-MAPK-PLA2G4E axis, expanding the mechanistic understanding of RTK inhibitors and proposing metabolic pathway-targeted combination therapies for HCC.